Nancy Klauber DeMore

Durham, NC, United States of America

Nancy Klauber DeMore

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 58(Granted Patents)


Location History:

  • Hanscom, AFB, US (2000)
  • Durham, NC (US) (2002 - 2015)
  • Charleston, SC (US) (2022)
  • Mount Pleasant, SC (US) (2024)

Company Filing History:


Years Active: 2000-2025

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Nancy Klauber DeMore: Innovator in Antibody Research

Introduction

Nancy Klauber DeMore is a prominent inventor based in Durham, NC (US). She has made significant contributions to the field of antibody research, particularly in the development of humanized antibodies targeting SFRP2. With a total of 7 patents, her work has the potential to impact the treatment of various diseases, including cancer.

Latest Patents

One of her latest patents focuses on compositions and methods comprising SFRP2 antagonists. This patent provides humanized antibodies and antigen-binding fragments that specifically bind to SFRP2. These compositions can be utilized to treat diseases associated with increased SFRP2 levels, such as cancer and osteosarcoma. The innovative nature of her work lies in the potential therapeutic applications of these antibodies.

Career Highlights

Throughout her career, Nancy has been associated with the University of North Carolina at Chapel Hill, where she has contributed to groundbreaking research. Her expertise in antibody development has positioned her as a key figure in her field.

Collaborations

Nancy has collaborated with notable professionals, including Cam Patterson and Robert J D'Amato. These partnerships have further enhanced her research and innovation in antibody therapies.

Conclusion

Nancy Klauber DeMore's contributions to antibody research exemplify her dedication to advancing medical science. Her innovative patents and collaborations highlight her role as a leading inventor in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…